Group 1 - The core viewpoint of the article highlights that Health 160, a Chinese pharmaceutical and health product wholesaler, has successfully completed its IPO subscription with a total subscription amount of at least HKD 25.24 billion, resulting in an oversubscription of 503.8 times [1] - Health 160 plans to issue a total of 33.6455 million shares, with approximately 10% allocated for public offering and 90% for international offering, at a price of HKD 14.86 per share, aiming to raise around HKD 500 million [1] - The company does not have a mandatory replenishment mechanism for the public offering, allowing the overall coordinator to increase the number of shares available for public offering to 5.04675 million shares, which is 15% of the initial offering [1] Group 2 - Health 160 is described as an experienced wholesaler of pharmaceutical and health products and a leading provider of digital healthcare services, offering a variety of health products and comprehensive digital healthcare solutions [2] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [2] - Financially, the company's revenues for the years ending March 31 for 2022, 2023, 2024, and 2025 were approximately CNY 526 million, CNY 629 million, CNY 621 million, and CNY 100 million, respectively, with corresponding losses of approximately CNY 120 million, CNY 106 million, CNY 108 million, and CNY 17.128 million [2]
新股消息 | 健康160(02656)招股结束 孖展逾252亿港元超购504倍